Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region
Sponsor: Hikma Pharmaceuticals LLC
A observational or N/A phase clinical study on Relapsing Remitting Multiple Sclerosis, this trial is completed. The trial is conducted by Hikma Pharmaceuticals LLC and has accumulated 7 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Oct 2023 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Apr 2023 — Oct 2023 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Oct 2021 — Apr 2023 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Not Yet Recruiting
-
Aug 2020 — Jan 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hikma Pharmaceuticals LLC
For direct contact, visit the study record on ClinicalTrials.gov .